http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018534316-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2016-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018534316-A |
| titleOfInvention | Pyrrolopyrimidine compounds as MNK inhibitors |
| abstract | The present invention relates to compounds of formula I, or pharmaceutically acceptable salts or esters thereof, Wherein R 1 is selected from H and CO—NR 8 R 9 , and R 8 and R 9 are each independently selected from H, alkyl, cycloalkyl and monocyclic or bicyclic heterocycloalkyl. The alkyl group may be substituted by one or more R 12 groups, the heterocycloalkyl may be substituted by R 10 or R 12 , or R 8 and R 9 may be Linked together with the attached nitrogen may contain one or more additional heteroatoms, substituted by one or more groups selected from R 10 and (CH 2 ) m R 12 also forming a good heterocycloalkyl group optionally, R 2 is selected from H and alkyl is, the alkyl group may be substituted by one or more R 12 groups, R 3 is Le is selected from cycloalkyl and heterocycloalkyl, each of which halo, it may be substituted by OH or alkoxy, Z 1, Z 2, Z 3 and Z 4 are all C, R 4 , R 5 , R 6 and R 7 are each independently selected from H, alkyl, CN, NO 2 , OH, alkoxy, NHCO-alkyl, halo and haloalkyl, or Z 1 , Z 3 and Z 4 Are all C, Z 2 is N, R 5 is absent, R 4 , R 6 and R 7 are as defined above, or Z 2 , Z 3 and Z 4 are all C Yes, Z 1 is N, R 4 is absent, R 5 , R 6 and R 7 are as defined above, R 10 and R 11 are each independently alkyl, and R 12 is Each independently Selected from CO 2 R 10 , COOH, OH, alkoxy, haloalkyl, NH 2 , NHR 10 , NR 10 R 11 , heteroaryl and heterocycloalkyl, R 13 is H or halo. Another aspect is a pharmaceutical composition and an uncontrolled cell growth, proliferation and / or survival, inappropriate cellular immune response, inappropriate cellular inflammatory response disease, or neurodegenerative disorder, preferably tauopathy And even more preferably the therapeutic use of said compounds in the treatment of Alzheimer's disease. [Chemical 1] |
| priorityDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 527.